FDA
-
-
-
-
-
-
-
Canaccord Genuity Reiterates Buy Rating on AxoGen, Inc. (AXGN)
-
-
-
-
-
-
-
Axogen receives FDA approval for AVANCE nerve allograft biologics license
-
-
-
-
-
-
-
Axogen receives three-month FDA review extension for Avance Nerve Graft
-
-
-
-
-
-
-
Axogen, Inc. Reports 2024 Fourth Quarter and Full-Year Financial Results
-
-
-
-
-
-
-
Axogen Processing Center (APC) Celebrates its Opening with Ohio Leaders in Vandalia
-
-
-
-
-
-
-
Axogen, Inc. Reports 2023 Second Quarter Financial Results
-
-
-
-
-
-
-
Axogen RECON(SM) Clinical Study Completes Subject Follow-up
-
326,551 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

